Condition (MeSH)
Hemolytic-Uremic Syndrome
ClinicalTrials.gov lists 68 trials for Hemolytic-Uremic Syndrome or a narrower condition beneath it. Alexion Pharmaceuticals, Inc. has the most among industry and government lead sponsors, with 16.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
26 of the 68 trials are tagged with Hemolytic-Uremic Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Hemolytic-Uremic Syndrome trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 6 |
| 2023 | 5 |
| 2022 | 3 |
| 2021 | 5 |
| 2020 | 1 |
| 2019 | 4 |
| 2018 | 5 |
| 2017 | 3 |
Showing 10 of 22 earlier years.
No forecast is made for this condition: it averages 4.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 38 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hemolytic-Uremic Syndrome trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 15 |
| Phase 2/3 | 1 |
| Phase 3 | 14 |
| Phase 4 | 3 |
| Not applicable | 7 |
| Observational | 25 |
| Expanded access | 1 |
How many Hemolytic-Uremic Syndrome trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 15 |
| Active, not recruiting | 4 |
| Available | 1 |
| Completed | 28 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hemolytic-Uremic Syndrome trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Alexion Pharmaceuticals, Inc. | 16 |
| AstraZeneca | 4 |
| Novartis Pharmaceuticals | 3 |
| Hoffmann-La Roche | 2 |
| Omeros Corporation | 2 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Hemolytic-Uremic Syndrome? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Eculizumab | 13 |
| Ravulizumab | 5 |
| OMS721 | 3 |
| Iptacopan | 2 |
| Crovalimab | 2 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| INM004 | 3 |
| Cemdisiran | 2 |
| D. Midazolam | 1 |
| SYNSORB Pk | 1 |
| Tac+MTX | 1 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hemolytic-Uremic Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| SAE by System Organ | 71 | 1 |
| Death | 44 | 1 |
| Hypertension | 15 | 8 |
| Pneumonia | 13 | 6 |
| Renal impairment | 13 | 7 |
Showing 5 of 10 adverse events.
Which publications cover Hemolytic-Uremic Syndrome? (57)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome. | The Cochrane database of systematic reviews | 2025 | Yes |
| Long-term kidney outcomes in non-dialyzed children with Shiga-toxin Escherichia coli associated hemolytic uremic syndrome. | Pediatric nephrology (Berlin, Germany) | 2023 | Yes |
| Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. coli Infection: a multinational embedded cluster crossover randomized trial (the HIKO STEC trial). | Trials | 2023 | Yes |
| Erythropoietin in children with hemolytic uremic syndrome: a pilot randomized controlled trial. | Pediatric nephrology (Berlin, Germany) | 2022 | Yes |
| Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome. | The Cochrane database of systematic reviews | 2021 | Yes |
Showing 5 of 57 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Hemolytic uremic syndrome | 544458 | Exact | Orphadata Science knowledge files, Product 1 |
| Hemolytic uremic syndrome | 544458 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence.